Clinical trial
ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast…
NCT00404404 · Premiere Oncology, Other · Unknown status
Key facts
| NCT number | NCT00404404 |
|---|---|
| Title | ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer |
| Official title | Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With Bevacizumab in Metastatic Breast Cancer |
| Lead sponsor | Premiere Oncology, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation |
| Enrollment | 35 |
| Start date | Oct 1, 2006 |
| First posted | Nov 28, 2006 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: